DMK Pharmaceuticals reports preclinical results on DPI-125

DMK Pharmaceuticals announced the presentation of preclinical results comparing the effects of DPI-125 on opioid withdrawal behaviors to methadone and buprenorphine, the standard of care for opioid use disorder, or OUD, in a poster session at the Society for Neuroscience Annual Meeting held November 11-13, 2023 in Washington D.C. “Only about 12% of patients receive treatment for OUD, despite the proven efficacy of current medications. Buprenorphine, the market leader with US sales in excess of $3B in 2022, requires an induction phase to induce withdrawal symptoms prior to initiating the first dose. It is challenging for a patient to voluntarily experience these symptoms. In addition, buprenorphine can be abused. For this and other reasons, widespread adoption is low. We believe that DPI-125, our novel clinical stage compound, will be able to overcome this and several other barriers to treatment initiation and maintenance. The positive data to be presented today marks the first step to realizing this promise. We are excited to present preclinical data comparing DPI-125, a triple opioid agonist, to the standard of care treatments buprenorphine and methadone to alleviate withdrawal symptoms. This preclinical study was financially supported by a grant from the National Institute of Drug Abuse, and we believe that it warrants further development,” said Eboo Versi, M.D., Ph.D., CEO of DMK Pharmaceuticals.